NCT00002187已完成不适用
A Randomized Comparison of Two Dosage Schedules of Intravitreal ISIS 2922 for Patients With Advanced Cytomegalovirus Retinitis
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 试验地点
- 17
研究概览
简要总结
The purpose of this study is to compare the safety and effectiveness of two dosage schedules for ISIS 2922 in the treatment of advanced cytomegalovirus (CMV) retinitis
详细描述
This is a multicenter, prospective, randomized, open-label study comparing 2 dosage schedules of ISIS 2922.
研究设计
- 研究类型
- Interventional
- 干预模型
- Parallel
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Concurrent Medication:
- •Oral ganciclovir.
- •Leukocyte growth factors (GM-CSF and G-CSF) for patients with febrile neutropenia.
- •Patients must have:
- •Documented AIDS.
- •Clinical diagnosis of advanced CMV retinitis in 1 or both eyes.
- •>= 2 previous induction courses with anti-CMV retinitis therapy licensed by a regulatory agency.
- •> 25% retinal involvement with CMV retinitis.
- •Baseline CMV retinitis lesions which have leading edges > 1000 micrograms from the macula or optic disk.
- •Prior Medication:
- •>= 2 previous induction courses with anti-CMV retinitis therapy licensed by a regulatory agency.
- •All anti-CMV therapies other than ganciclovir must be discontinued no less than 2 days prior to entry.
排除标准
- •Co-existing Condition:
- •Patients with the following symptoms and conditions are excluded:
- •External ocular infection in the eye to be treated.
- •Other herpetic infections of the retina, toxoplasma, retinochoroiditis, or other disease of the fundus that would preclude assessment of CMV retinitis in the eye to be treated.
- •Ocular conditions that will obstruct visualization of the posterior ocular structures on the eye to be treated.
- •Retinal detachment in the eye to be treated.
- •Ganciclovir implant in the eye to be treated.
- •Known or suspected allergy to phosphorothioate oligonucleotides or intolerance of ISIS
- •Silicone oil in the eye to be treated.
- •Pseudoretinitis pigmentosa.
- •Syphilis.
- •Patients with the following prior conditions are excluded:
- •History of surgery to correct retinal detachment in the eye to be treated.
- •History of syphilis.
- •1. Systemic anti-CMV therapies other than oral ganciclovir.
- •Mellaril, Stelazine, chlorpromazine and clofazimine.
- •Combination use of ethambutol and fluconazole.
- •Investigational medications and/or procedures for the treatment of CMV retinitis in the eye to be treated.
- •Ganciclovir implant delivery device in the eye to be treated.
- •Ganciclovir other than oral.
- •Foscarnet.
研究者
研究点 (17)
Loading locations...
相似试验
已完成
2 期
2 Arm Study of Clofarabine IV in MDS PatientsLeukemiaMyelodysplastic SyndromeNCT00422032M.D. Anderson Cancer Center60
已完成
3 期
Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone LesionsBreast Cancer With Bone MetastasisNCT00375427Novartis Pharmaceuticals430
已完成
2 期
Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)LeukemiaNCT01786343M.D. Anderson Cancer Center74
撤回
4 期
A Randomized Study to Compare the Dosing Schedule of INFeD in Anemic Patients.Anemia, Iron DeficiencyNCT03286205Sutter Gould Medical Foundation
已完成
2 期
A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo to Reduce the Need for Blood Transfusions and Reduce the Occurrence of Severe Anemia During the Time Period Surrounding Total Hip Replacement SurgeryAnemiaNCT00269958Janssen-Ortho Inc., Canada208